Trial Profile
Bioavailability of Alternate Dosing Options of Dexlansoprazole 30 mg modified-release orally disintegrating tablet
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2014
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary) ; Dexlansoprazole (Primary)
- Indications Erosive oesophagitis; Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors Takeda Global Research and Development Center
- 10 Aug 2014 New trial record